Tag: clinical biomarkers

Héctor Pérez Montoyo, of Ability Pharma discusses his research on, “ABTL0812, a new immunotherapeutic anticancer agent at phase 2b clinical stage.”

MarketsandMarkets Conferences
Héctor Pérez Montoyo, of Ability Pharma discusses his research on, “ABTL0812, a new immunotherapeutic anticancer agent at phase 2b clinical stage.”

Héctor’s work has always focused on understanding the molecular pathophysiological mechanisms leading to autoimmunity and cancer development, investigating mechanism of action of newly developed molecules to treat such diseases. He started his career in 2006 when he moved to UT Southwestern Medical Center in Dallas (EEUU), to carry out this thesis in developing novel therapeutic antibodies in murine models of human autoimmune diseases. After obtaining his Ph.D., he combined two postdoctoral grants in Barcelona (Metastasis and Transformation group in Bellvitge Biomedical Research Center) and in Valencia (Autoimmune Pathology Lab in…

Read More

Speaker Interview with Dr. Susan Astley for MarketsandMarkets Biomarker and Companion Diagnostics Conference

MarketsandMarkets Conferences
Speaker Interview with Dr. Susan Astley for MarketsandMarkets Biomarker and Companion Diagnostics Conference

London, September 3, 2019 – MarketsandMarkets recently interviewed Dr. Susan Astley, Division of Informatics, Imaging & Data Sciences, University of Manchester regarding MarketsandMarkets Biomarker and Companion Diagnostics Conference taking place on 3rd – 4th October 2019 at Radisson Blu Edwardian, Grafton, London, UK Q. What are the recent advances in Biomarker research/commercialization and current challenges that need immediate attention? A. The era of personalised medicine is with us. Biomarkers are crucial to identify those at risk of particular diseases, and those who would benefit from different preventative or therapeutic interventions….

Read More